WO2005116052A3 - ANTAGONISM OF TGF-β SUPERFAMILY RECEPTOR SIGNALING - Google Patents

ANTAGONISM OF TGF-β SUPERFAMILY RECEPTOR SIGNALING Download PDF

Info

Publication number
WO2005116052A3
WO2005116052A3 PCT/US2005/014570 US2005014570W WO2005116052A3 WO 2005116052 A3 WO2005116052 A3 WO 2005116052A3 US 2005014570 W US2005014570 W US 2005014570W WO 2005116052 A3 WO2005116052 A3 WO 2005116052A3
Authority
WO
WIPO (PCT)
Prior art keywords
tgf
antagonism
type
receptor signaling
superfamily
Prior art date
Application number
PCT/US2005/014570
Other languages
French (fr)
Other versions
WO2005116052A2 (en
Inventor
Craig Harrison
Peter Gray
Wolfgang Fischer
Senyon Choe
Wylie Vale
Original Assignee
Res Dev Foundation
Craig Harrison
Peter Gray
Wolfgang Fischer
Senyon Choe
Wylie Vale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation, Craig Harrison, Peter Gray, Wolfgang Fischer, Senyon Choe, Wylie Vale filed Critical Res Dev Foundation
Priority to AU2005247871A priority Critical patent/AU2005247871A1/en
Priority to EP05780041A priority patent/EP1740609A2/en
Priority to CA002563374A priority patent/CA2563374A1/en
Publication of WO2005116052A2 publication Critical patent/WO2005116052A2/en
Publication of WO2005116052A3 publication Critical patent/WO2005116052A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Abstract

Members of the TGF-β superfamily control many physiologic and pathophysiologic processes in multiple tissues and signal via type II and type I receptor serine kinases. Type II activin receptors are promiscuous and known to bind 12 TGF-β ligands including activins, myostatin, BMPs and nodal. Methods are described for the screening and identification of antagonist for TGF-β superfamily members, in particular activin-A antagonist.
PCT/US2005/014570 2004-04-27 2005-04-27 ANTAGONISM OF TGF-β SUPERFAMILY RECEPTOR SIGNALING WO2005116052A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2005247871A AU2005247871A1 (en) 2004-04-27 2005-04-27 Antagonism of TGF-beta superfamily receptor signaling
EP05780041A EP1740609A2 (en) 2004-04-27 2005-04-27 Antagonism of tgf-beta superfamily receptor signaling
CA002563374A CA2563374A1 (en) 2004-04-27 2005-04-27 Antagonism of tgf-.beta.superfamily receptor signaling

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56559404P 2004-04-27 2004-04-27
US60/565,594 2004-04-27

Publications (2)

Publication Number Publication Date
WO2005116052A2 WO2005116052A2 (en) 2005-12-08
WO2005116052A3 true WO2005116052A3 (en) 2006-06-08

Family

ID=35451452

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/014570 WO2005116052A2 (en) 2004-04-27 2005-04-27 ANTAGONISM OF TGF-β SUPERFAMILY RECEPTOR SIGNALING

Country Status (5)

Country Link
US (1) US7575751B2 (en)
EP (1) EP1740609A2 (en)
AU (1) AU2005247871A1 (en)
CA (1) CA2563374A1 (en)
WO (1) WO2005116052A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5199885B2 (en) * 2006-01-18 2013-05-15 アムジエン・インコーポレーテツド Thiazole compounds as protein kinase B (PKB) inhibitors
CL2007002567A1 (en) 2006-09-08 2008-02-01 Amgen Inc ISOLATED PROTEINS FROM LINK TO ACTIVINE TO HUMAN.
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
US10059756B2 (en) 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
EP3275900A1 (en) 2009-04-27 2018-01-31 Novartis AG Compositions and methods for increasing muscle growth
US20150359850A1 (en) 2009-11-25 2015-12-17 Santa Maria Biotherapeutics, Inc. Administration of an anti-activin-a compound to a subject
US9856305B2 (en) 2010-08-20 2018-01-02 Wyeth Llc Designer osteogenic proteins
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
CN105198981B (en) * 2010-08-20 2019-07-16 惠氏有限责任公司 Osteogenic protein through designing
WO2012138223A2 (en) * 2011-04-05 2012-10-11 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Compounds and methods for altering activin receptor-like kinase signalling
EP3426680A4 (en) 2016-03-10 2020-03-11 Acceleron Pharma Inc. Activin type 2 receptor binding proteins and uses thereof
GB201709636D0 (en) * 2017-06-16 2017-08-02 Cambridge Entpr Ltd Follistatin-Resistant Activin

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2720069A1 (en) * 1994-05-19 1995-11-24 Inst Nat Sante Rech Med Variants of transforming growth factor-beta proteins

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4886747A (en) 1985-03-22 1989-12-12 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
US5284763A (en) 1985-03-22 1994-02-08 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
NZ217727A (en) 1985-10-03 1990-05-28 Genentech Inc Nucleic acid encoding alpha or b chain of inhibin, its production and compositions containing it
US5108922A (en) 1986-07-01 1992-04-28 Genetics Institute, Inc. DNA sequences encoding BMP-1 products
US5013649A (en) 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
US5106748A (en) 1986-07-01 1992-04-21 Genetics Institute, Inc. Dna sequences encoding 5 proteins
ZA874681B (en) 1986-07-01 1988-04-27 Genetics Inst Novel osteoinductive factors
US5187076A (en) 1986-07-01 1993-02-16 Genetics Institute, Inc. DNA sequences encoding BMP-6 proteins
US5221620A (en) 1987-10-06 1993-06-22 Oncogen Cloning and expression of transforming growth factor β2
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
ATE167486T1 (en) 1989-10-17 1998-07-15 Stryker Corp OSTEOGENIC DEVICES
ATE209251T1 (en) 1990-05-16 2001-12-15 Genetics Inst PROTEINS PRODUCING BONE AND CARTILAGE FORMATION
EP0652951B1 (en) 1990-06-15 1999-09-01 Carnegie Institution Of Washington GDF-1and UOG-1 proteins
US5652337A (en) 1991-03-11 1997-07-29 Creative Biomolecules, Inc. OP-3-induced morphogenesis
EP0592562B1 (en) 1991-06-25 1999-01-07 Genetics Institute, Inc. Bmp-9 compositions
RU2208638C2 (en) 1992-02-12 2003-07-20 Биофарм Гезельшафт Цур Биотехнологишен Энтвиклунг фон Фармака мбХ Dna (variants), method for preparing protein, protein, pharmaceutical composition
IL106278A0 (en) 1992-07-13 1993-11-15 Sumitomo Metal Ind Bone formation-inducing protein
JP3645258B2 (en) 1993-01-12 2005-05-11 ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン Growth and differentiation factor-5
ES2201076T3 (en) 1993-03-19 2004-03-16 The Johns Hopkins University School Of Medicine GROWTH DIFFERENTIATION FACTOR-8.
EP0698094B1 (en) 1993-05-12 2004-02-04 Genetics Institute, LLC Bmp-11 compositions
AU677849B2 (en) 1993-05-12 1997-05-08 Genetics Institute, Llc BMP-10 compositions
AU688779B2 (en) 1993-07-09 1998-03-19 Johns Hopkins University School Of Medicine, The Growth differentiation factor-7
US5770444A (en) 1993-07-09 1998-06-23 The Johns Hopkins University School Of Medicine Growth differentiation factor-6
IL110589A0 (en) 1993-08-10 1994-11-11 Bioph Biotech Entw Pharm Gmbh Growth/differentiation factor of the TGF- beta family
US6204047B1 (en) 1993-10-08 2001-03-20 The Johns Hopkins University School Of Medicine Growth differentiation factor-10
JP3300500B2 (en) 1993-10-12 2002-07-08 新日本製鐵株式会社 Method for producing hot forging steel excellent in fatigue strength, yield strength and machinability
ES2255059T3 (en) 1993-12-07 2006-06-16 Genetics Institute, Llc BMP-12, BMP-13 AND YOUR INDUCTION COMPOSITIONS OF TENDON.
US6027919A (en) 1993-12-07 2000-02-22 Genetics Institute, Inc. BMP-12 and BMP-13 proteins and DNA encoding them
IL114397A0 (en) 1994-07-01 1995-10-31 Bioph Biotech Entw Pharm Gmbh Growth/differentiation factor of the TGF-beta-family
EP0776337B1 (en) 1994-07-08 2005-09-21 The Johns Hopkins University School Of Medicine Growth differentiation factor-11
EP0770089B1 (en) 1994-07-13 2000-09-06 The Johns Hopkins University School Of Medicine Growth differentiation factor-12
WO1996014335A1 (en) 1994-11-07 1996-05-17 The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Health And Human Services Cartilage-derived morphogenetic proteins
US5635372A (en) 1995-05-18 1997-06-03 Genetics Institute, Inc. BMP-15 compositions
NZ310370A (en) 1995-06-22 2001-04-27 St A TGF-beta like cytokine designated pCL13
US6524802B1 (en) 1996-03-29 2003-02-25 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-14
US5965403A (en) 1996-09-18 1999-10-12 Genetics Institute, Inc. Nucleic acids encoding bone morphogenic protein-16 (BMP-16)
JP2001505420A (en) 1996-11-20 2001-04-24 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン Liver activin / inhibin nucleotide and protein sequences and methods based thereon
AU8591198A (en) 1997-07-31 1999-02-22 Johns Hopkins University School Of Medicine, The Growth differentiation factor-15

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2720069A1 (en) * 1994-05-19 1995-11-24 Inst Nat Sante Rech Med Variants of transforming growth factor-beta proteins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FISCHER W H ET AL: "Residues in the C-terminal region of activin A determine specificity for follistatin and type II receptor binding.", JOURNAL OF ENDOCRINOLOGY, vol. 176, no. 1, January 2003 (2003-01-01), pages 61 - 68, XP002372264, ISSN: 0022-0795 *
HARRISON CRAIG A ET AL: "An activin mutant with disrupted ALK4 binding blocks signaling via type II receptors", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, no. 27, 2 July 2004 (2004-07-02), pages 28036 - 28044, XP002372283, ISSN: 0021-9258 *
HARRISON CRAIG A ET AL: "Identification of a functional binding site for activin on the type I receptor ALK4.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 23, 6 June 2003 (2003-06-06), pages 21129 - 21135, XP002372265, ISSN: 0021-9258 *
MASSAGUE J: "TGF-BETA SIGNAL TRANSDUCTION", ANNUAL REVIEW OF BIOCHEMISTRY, PALTO ALTO, CA, US, vol. 67, 1998, pages 753 - 791, XP000982012, ISSN: 0066-4154 *

Also Published As

Publication number Publication date
CA2563374A1 (en) 2005-12-08
US20060008846A1 (en) 2006-01-12
US7575751B2 (en) 2009-08-18
AU2005247871A1 (en) 2005-12-08
EP1740609A2 (en) 2007-01-10
WO2005116052A2 (en) 2005-12-08

Similar Documents

Publication Publication Date Title
WO2005116052A3 (en) ANTAGONISM OF TGF-β SUPERFAMILY RECEPTOR SIGNALING
WO2005028517A3 (en) SOLUBLE TGF-β TYPE III RECEPTOR FUSION PROTEINS
WO2000006085A3 (en) Compounds and methods
WO2005023806A3 (en) Heteroaryl fused pyridines, pyrazines and pyrimidines as crf1 receptor ligands
WO2004100875A3 (en) Benzimidazoles, compositions containing such compounds and methods of use
DE50210986D1 (en) SUBSTITUTED 2-THIO-3,5-DICYANO-4-PHENYL-6-AMINOPYRIDINE AND THEIR USE AS ADENOSINE RECEPTOR SELECTIVE LIGANDS
PL379009A1 (en) Pyrazolo[1,5-a][1,3,5]triazine derivatives as cannabinoid receptor ligands
WO2002053533A3 (en) Kappa opioid receptor ligands
EP1844082A4 (en) Mixed supported metallocene catalyst, method of preparing the same, method of preparing polyolefin using the mixed supported metallocene catalyst, and polyolefin prepared using the method of preparing polyolefin using the mixed supported metallocene catalyst
WO2007027734A3 (en) Bicyclic and bridged nitrogen heterocycles
WO2004010929A3 (en) METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-β INHIBITORS
WO2005105803A3 (en) Purine derivatives as a1 adenosine receptor antagonists
WO2006060513A3 (en) Toll like receptor 3 antagonists, methods and uses
WO2004069158A3 (en) Substituted pyrazoles, compositions containing such compounds and methods of use
DE50213525D1 (en) SUBSTITUTED 2, 6-DIAMINO-3, 5-DICYANO-4-ARYL-PYRIDINE AND THEIR USE AS ADENOSINE RECEPTOR SELECTIVE LIGANDS
IL140622A0 (en) Biphenyl sufonamide derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
WO2001044239A3 (en) Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
WO2006104826A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
AU2001228212A1 (en) Beta-turn peptidomimetic cyclic compounds
MX2009005358A (en) 5-sulfanylmethyl-pyrazolo [1,5-a] pyrimidin-7-ol derivatives as cxcr2 antagonists.
WO2004032852A3 (en) Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
ZA200608412B (en) Novel 2-[1-aza-bicyclo (2.2.2)oct-3-yl)-2,3-dihydroisoindol-1-one/5/6-dihydro-furo[2,3-c]pyrrol-4one derivatives ligands for alpha 7 nicotinic acetylcholine receptor
HK1088320A1 (en) Pyrrole-2, 5-dione derivatives as liver x receptor modulators
WO2007014263A3 (en) Octahydroisoquinoline compounds as opioid receptor modulators
MX2009005174A (en) 5-sulfanylmethyl-[1,2,4] triazol[1, 5-a] pyrimidin-7-ol derivatives as cxcr2 antagonists.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2563374

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005247871

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005780041

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005247871

Country of ref document: AU

Date of ref document: 20050427

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005247871

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005780041

Country of ref document: EP